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Background: Compelling evidence suggests that inhibition of the complex I of the electron transport chain and
elevated oxidative stress are the earliest events during the pathogenesis of Parkinson’s disease (PD). Therefore,
anti-oxidants, especially those from natural sources, hold good promise in treating PD as demonstrated mostly by
the studies in rodent models.
Results: Herein, we determined if polydatin (piceid), a natural polyphenol, could exert anti-oxidative activity and
attenuate dopaminergic neurodegeneration in three commonly used rodent models of PD. Male Sprague Dawley
rats given rotenone subcutaneously for 5 weeks developed all the essential features of PD, including a strong
increase in catalepsy score and a decrease in motor coordination activity, starting at 4 weeks. Selective increase in
oxidative damage was found in the striatal region as compared to the hippocampus and cortex, accompanied by
massive degeneration of dopaminergic neurons in the substantia nigra (SNc). Co-administration of piceid orally was
able to attenuate rotenone-induced motor defects in a dose dependent manner, with 80 mg/kg dosage showing
even better effect than L-levodopa (L-dopa). Piceid treatment significantly prevented the rotenone-induced changes
in the levels of glutathione, thioredoxin, ATP, malondialdehyde (MDA) and the manganese superoxide dismutases
(SOD) in striatum. Furthermore, piceid treatment rescued rotenone-induced dopaminergic neurodegeneration in
the SNc region. Similar protective effect of piceid was also observed in two additional models of PD, MPTP in mice
and 6-OHDA in rats, showing corrected motor functions, SOD and MDA activities as well as p-Akt and activated
caspase-3 levels.
Conclusion: In three rodent models of PD, piceid preserves and corrects several major anti-oxidant pathways/
parameters selectively in the affected SNc region. This implies its potent anti-oxidant activity as one major
underscoring mechanism for protecting the vulnerable SNc neurodegeneration in these models. Taken together,
these findings strongly suggest a therapeutic potential of piceid in treating PD.
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Parkinson’s disease (PD) is a devastating disease and the
second most common neurodegenerative disease, afflict-
ing over four million individuals. Pathologically, it is char-
acterized by the loss of dopaminergic neurons in the
substantia nigra pars compacta (SNc), which is attributed
to both environmental and genetic factors. Mitochondrial
impairment, oxidative stress, α-synuclein aggregation and
impaired protein degradation have all been implicated in
PD pathogenesis. Compelling evidence suggests that in-
hibition of the complex I of the electron transport chain
and elevated oxidative stress (ROS) are the earliest events,
followed by modifications of α-synuclein and proteasomal
dysfunction, leading ultimately to neurodegeneration [1].
Therefore, anti-oxidants hold promise in treating PD.
It is well-known that a diet rich in fruit and vegetables
helps to prevent aging-related disorders, cardiovascular
diseases and cancer. This effect may be attributed to the
antioxidant activity of polyphenols in fruits and vegetables.
Polyphenols, such as resveratrol in grapes, are thought to
account for the “French Paradox” which associates red
wine consumption with a low incidence of cardiovascular
diseases [2]. Despite the identification of multiple benefi-
cial properties (e.g., antioxidant, anti-inflammation, anti-
carcinogenic and anti-aging etc.) [3,4], resveratrol does
not display favorable pharmacological properties due to its
poor oral bioavailability and rapid clearance rate [5,6].
Polydatin (piceid, [3, 4′, 5-trihydroxystilbene-3-β-mono-
D-glucoside]) is a non-glycosylated derivative of resvera-
trol [3,4=,5-trihydroxystibene] and is the most abundant
form of resveratrol in nature [7] (Figure 1). Piceid’s anti-
oxidant properties are largely unknown. When piceid and
resveratrol were compared in terms of their antioxidant
properties in lipid peroxidation in one study, piceid ap-
pears to be more efficacious [8].
Owing to the fact that it is the most abundant form of
resveratrol, it is largely available in non-alcoholic grape
juices and is the major extracted component of a widely
used traditional Chinese herbal medicine (Polygonum
cuspidatum), piceid is believed to represent a new medi-
cation with modality. The Chinese FDA has approved it
for multiple phase II clinical trials in China mainly for
anti-shock applications. Piceid has been shown to be
neuroprotective in rodent models of focal ischemiaFigure 1 Chemical structures of trans-resveratrol and piceid.[9,10] as well as in hemorrhage shock treatment [11].
Although resveratrol has been demonstrated to be bene-
ficial in treating stroke [12], spinal cord injury [13] and
dopaminergic neurodegeneration in the PD models
induced by 6-OHDA and MPTP [14-16], there is no
report on piceid in these applications.
In this study, we aimed to evaluate the effect of piceid
in treating PD using three rodent models. Rotenone, a
commonly used natural pesticide extracted from the
roots of tropical plants of the genera Lonchocarpus and
Derris, is a potent specific inhibitor of mitochondrial
complex I of the electron transport chain. Chronic sys-
temic administration of rotenone in rodents has recently
been demonstrated to be a feasible model of PD by several
groups since it induces dopaminergic neurodegeneration,
as well as displaying the behavioral, neurochemical (e.g.,
elevated ROS and depleted ATP in mitochondria) and
neuropathological hallmarks of PD [17-22]. However, cer-
tain discrepancy has arisen from several recent reports in
terms of reproducibility, showing non-selective neuro-
degeneration or even overall systemic toxicity [23-28].
Therefore, comparing to the MPTP- and 6-OHDA-
induced models, rotenone model (especially systemically
administrated rotenone) is still not fully validated as a
widely used PD model. We therefore focused a great part
of our study to develop and validate a systemic rotenone
model. After we observed significant protective effect of
piceid in MPTP mouse and 6-OHDA rat models, we
tested the compound at different dosages and in compari-
son with L-Dopa (a “gold-standard” treatment of Parkin-
sonism) in our validated rotenone model; the majority of
data are presented from this model.
Results
Chronic administered rotenone induced multiple PD-like
motor deficits in rats
In a pilot experiment to develop a systemic rotenone
model, we chose to test a 2.5 mg/kg/d subcutaneous
regimen based on the literature; it appears that most
of the studies that generated selective SNc lesion used
2–3 mg/kg/d of rotenone. Subcutaneously (s.c.) injected
rotenone at this dosage daily to young adult male SD rats
(N = 8) was found to result in severe mortality (~60%
mortality) by the end of 4 weeks. We therefore adjusted
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mortality rate to < 10%; one out of 12 rats was dead. Tol-
erable weight loss (~20%) was observed during the 4-5th
week period. Pilot behavioral tests for motor functions
indicated severe impairment induced by this regimen of
rotenone; rotenone administration for longer than 5 weeks
led to increased mortality and > 25% weight loss Based on
these pilot studies, we therefore decided to use 2.0 mg/kg/d
rotenone s. c. for 5 weeks in the following experiments.
Effect of piceid on rotenone-induced catalepsy and motor
coordination disorder
During the 5-week acquisition trials in the catalepsy test
and rotarod motor coordination test, all the rats given
rotenone displayed progressive increases in cataleptic
behavior (a measure for rigidity) and decreases in motor
coordination and muscle activity as compared to the
vehicle group (Figure 2A and B). Prominent progression
was observed during the last two weeks, especially in the
5th week (p < 0.01). The motor coordination and muscle
performance of rotenone-treated rats decreased signifi-
cantly (Figure 2C).
In our pilot experiments, we tested piceid administra-
tion to rats via oral gavage daily in escalating dosages
(50–200 mg/kg/d) and found that it was well-tolerated
at the high dosage of 200 mg/kg/d after continuous ad-
ministration for 14 days. Biochemical analysis indicated
significantly increased anti-oxidant profiles (Trx, SOD
etc.) in all the three regions (hippocampi, cortex and
striatum) at these dosages with maximum effect obser-
ved at 100 or 200 mg/kg dosages of piceid (data not
shown). Like resveratrol [29], piceid is predicted to be
able to pass blood–brain-barrier. Indeed, our pilot tissue
distribution study supported its CNS permeability, though
its distributions in brain and skeletal muscle are much less
than that in liver, lung, kidney and intestines (data not
shown). Based on these data, we therefore chose a range
of dosages between 20–100 mg/kg in our next expe-
riments to be co-administrated with rotenone. Notably,
piceid prevented the progressive increases in catalepsy
when compared to the untreated rotenone-induced ani-
mals in a dose- and time-dependent manner (Figure 2A
and B). Based on the rats’ performance at the 5 week time
point, the 80 mg/kg piceid group displayed marked reduc-
tion (P < 0.01) while the 40 mg/kg piceid group showed
performance comparable to the 10 mg/kg L-dopa group.
For all three tests (Figure 2), 80 mg/kg piceid group per-
formed significantly better than the 10 mg/kg L-dopa
group (please see Figure legend for P values).
Effect of piceid on restoring rotenone-decreased ATP
Rotenone is believed to act on the mitochondrial elec-
tron transport chain and selectively inhibits complex I,
resulting in a dwindling supply of cellular energy, whichhas been implicated in the pathogenesis of PD. It was
also reported that rotenone completely prevented the
oxidation of pyruvate and many other physiological sub-
strates, thereby inhibiting ATP synthesis in mitochondria
[30]. We therefore determined the absolute levels of
intracellular ATP in the different brain regions (Cortex,
Hippocampus, Striatum). As shown in Figure 3A, rote-
none selectively reduced intracellular ATP in the stri-
atum by over 40% while high dosages (80 mg/kg) of
piceid largely restored the ATP level. These results indi-
cate the potent beneficial effect of piceid in restoring
mitochondrial energy levels impaired by rotenone.
Selective anti-oxidative effect of piceid in striatum
Lipid peroxidation was determined by measuring an end
product, MDA, in the different brain tissues after behav-
ioral testing. We found that rotenone increased MDA
levels in the striatum by almost 2-fold (P < 0.01) but not
in the other two brain regions (cortex and hippocampi)
(Figure 3B). Treatment with piceid or L-dopa both
reduced MDA levels in a dose-dependent manner, with
the high dosage (80 mg/kg) of piceid completely restor-
ing it to the basal level (P < 0.01). In addition to MDA,
we also investigated the other two most important anti-
oxidant defense molecules, GSH and SOD, and found
similar results (Figure 3C and D): piceid treatment at
80 mg/kg completely restored the levels of these two
molecules impaired by rotenone. Taken together, these
findings indicate the selective vulnerability of the striatum
to elevated oxidative stress and show the potent effect of
piceid in antagonizing ROS.
Effect of piceid on thiol antioxidant system-thioredoxin (Trx)
The Trx system is ubiquitous in all cells and is involved
in many redox-dependent signaling pathways [31]. Con-
sistent with the aforementioned ROS parameters, we
found selective reduction of the classical 12 kDa Trx
protein in the striatum after rotenone induction. This
was restored by piceid and L-dopa treatment with the
maximum effect achieved by the high dosage of piceid
(Figure 4).
Piceid’s protective effect on SNc neurodegeneration
induced by rotenone
Our data thus far collected from motor behavioral tests
and biochemical analysis all suggested selective neuropro-
tection of piceid in the striatal region. To further validate
our systemic rotenone model in generating selective SNc
neurodegeneration, we examined the rat tissues collected
by the end of our behavioral studies by histological means
and found that rotenone selectively induced damage in
the striatal region, as evidenced by increased eosino-
philic cells and swollen soma revolved by H & E staining
(Figure 5A). In contrast, the adjacent regions (cortex and
Figure 2 Effects of piceid and L-dopa on rotenone-induced catalepsy (A: grid test; B: bar test) and motor coordination disorder (C) for
rats in their 1st, 2nd, 3rd, 4th, and 5th week of treatment. Data is mean ± SEM of ten animals. #p < 0.05, ##p < 0.01 significant as compared
to vehicle treated animals of the respective week; *p < 0.05, **p < 0.01, significant as compared to the rotenone treated animals of the respective
week. Comparison between the 80 mg/kg/d piceid group and the 10 mg/kg L-dopa group yields P < 0.05 for the grid and motor coordination
tests and P <0.01 for the bar test. Rot: rotenone; Pic: piceid.
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Figure 3 Effects of piceid and L-dopa on rotenone-induced alterations to the levels of ATP (A), MDA (B), GSH (C), and SOD (D) in
different brain regions (Cortex, Hippocampus, Striatum). Data are expressed as mean ± SEM (n = 9/group). For statistical significance, # and
## indicate p < 0.05 and 0.005 as compared to the vehicle control group; ** indicates p < 0.005 as compared to the rotenone model group.
Significant difference between the 80 mg/kg piceid and 10 mg/kg L-dopa groups is P < 0.01.
Figure 4 Effects of piceid and L-dopa on the rotenone-induced alteration of Trx expression in different brain regions (Cortex, Hippocampus,
Striatum). A) Western blot analysis showing representative samples from each group (1 of 9 samples/group). B) Quantification based on all
9 samples in each group. Data are expressed as mean ± SEM (n = 9/group). For statistical significance, # and ## indicate p < 0.05 and 0.005 as
compared to the vehicle control group; ** indicates p < 0.005 as compared to the rotenone model group. Significant difference between the
80 mg/kg piceid and 10 mg/kg L-dopa groups is P < 0.05.


























Figure 5 Selective SNc neurodegeneration induced by rotenone and the rescuing effect of piceid. A) Coronal sections from the rostral to
caudal dopaminergic area containing neurons in the SNc were depicted by H&E staining. B) Representative TH-immunostained from coronal
sections containing the SNc regions. C) Quantification of the TH-immunoreactive neurons based on the scans of every 10th section of the striatum
(5 sections/animal × 5 animals per group) using Scion Image (Version 4.0.3.2 Scion Corporation, MD). Vehicle: sunflower oil + 0.5% CMC-Na 10; Pic:
piceid (80 mg/kg/d); Rot: rotenone (2.0 mg/kg/d). “**” indicates P < 0.01 as compared to the piceid treatment group.
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Rotenone also induced selective and massive loss of the
TH-immunostained neurons from the SNc region after
5-weeks (Figure 5B) which was largely rescued by piceid
treatment (80 mg/kg) (Figure 5C, p < 0.005).
Piceid also displayed potent anti-oxidant activity and
prevented/corrected motor dysfunctions in two additional
PD models
To verify the usefulness of oral piceid in preventing and
treating PD, we also tested the compound in MPTP-
induced mouse and 6-OHDA-induced rat models. Daily
oral piceid treatment on young male C57BL/6 mice
starting from the first day of subcutaneous injection of
MPTP (40 mg/kg for 7 days) for 14 days significantly
prevented motor deficits and preserved SOD activity (and
reduced MDA values) in the striatal region (Figure 6A-C;
Additional file 1: Figure S1-S4); 200 mg/kg of piceid per-
formed comparably with 25 mg/kg L-dopa. Interest-
ingly, combination of 100 mg/kg piceid with 12.5 mg/kg
achieved the same effect with either compound alone at
twice the dosage, indicating that piceid treatment can
achieve the same outcome as L-dopa. Furthermore, his-
tological and biochemical analysis of the striatal regionindicates markedly protective effect of piceid on TH-
positive DA neurons, survival signaling (e.g., increased
p-Akt and reduced activated caspase 3, Figure 6D-F).
In a 6-OHDA-induced PD model in rats, the apomorphine-
induced rotations of the 6-OHDA-lesioned rats were
significantly increased (10.89 ± 2.47 vs 0.44 ± 0.73 times/
min, n = 10 animals each group; P < 0.005). SOD activity
(166.51 ± 17.29 vs 89.28 ± 12.79) and MDA levels (5.94 ±
1.65 vs 10.88 ± 2.37) were also dramatically impaired by
6-OHDA (P <0.001). Strikingly, significant and sustained
effect was achieved with 50 mg/kg/d piceid starting a
few hours after 6-OHDA injection from 7 days and up
to 28 days (Figure 7A); the effect is comparable (slightly
better but no significant) with the 25 mg/kg L-dopa
group or 50 mg/kg piceid + 12.5 mg/kg L-dopa. Similarly,
the SOD and MDA activity/levels were significantly im-
proved by piceid treatment.
Discussion
Current treatments for PD are limited in effectiveness
and only improve the symptoms of the disease and don’t
address the cause. L-dopa, which increases brain levels
of dopamine, has been used for years and is the gold
standard for treating PD. It is currently the most effective
Figure 6 Effects of piceid and L-dopa on MPTP-induced PD in mice. Locomotor activity (A) and rotarod activity (B) on treated and untreated
C57BL/6 mice determined on the 15th day (N = 10 animals each troup). C) The actual SOD activity and MDA levels. “* and **” indicate P < 0.05
and 0.01, respectively, as compared to the MPTP-induced model group. L50 and L25 indicate L-Dopa at 50 and 25 mg/kg dosages, respectively.
D) Immunohistochemistry. Coronal sections of paraffin blots (6 μcrom) were stained with H & E, mouse anti-TH (both DAB and fluorescent readouts)
and antibodies against p-Akt (Ser374) and activated caspase-3. Representative images were chosen from a set of three mice each group. E) Western
blot analysis of the isolated SNc tissue (lysates pooled from 3 mice each group). Trx: thioredoxin; F) Quantification. “***” indicates P < 0.005 as compared
to the MPTP group.
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Figure 7 Effects of piceid and L-dopa on 6-OHDA-induced PD in rats. A) Number of apomorphine-induced rotations as determined on 7, 14,
21, and 28 days after 6-OHDA injection. N = at least 9 animals per group. * indicates P < 0.05 as compared to the 6-OHDA-induced model group.
B) The actual SOD activity and MDA levels. * and ** indicate P < 0.05 and 0.01, respectively, as compared to the model group.
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phases of the disease. However, this drug increases the risk
of involuntary movements (dyskinesia). Moreover, its ef-
fectiveness tends to decrease after 4–5 years of usage [32],
making discovery of a new drug imperative [33]. Elevated
oxidative stress has been reported in the brains of PD
patients [34]. Therefore, combining an antioxidant with
other protective agents would be a good therapeutic op-
tion for neurodegenerative diseases like PD. Polyphenols
represent one of the most promising categories of thera-
peutic candidates, owing to their potent protective and
anti-oxidative properties. Our present work demonstrates
that piceid displays strong anti-oxidative property and sys-
temic piceid administration can achieve preventive effects,
comparable or better than L-dopa in rescuing PD-like
motor deficits induced by rotenone, MPTP or 6-OHDA.
We should emphasize that in all three models, piceid
treatment can achieve at least the same beneficial out-
comes as with L-dopa in terms of motor behaviors and
DA neuronal cells. Although L-dopa is a typical antipar-
kinsonism acting by increasing dopamine activity, it is
not clear whether piceid other than its primary iden-
tity as an anti-oxidant, can also exert effect on dopa-
mine release/activity. Our data support its primaryrole in anti-oxidation and preserving DA neurons.
Therefore, the effect of piceid is more likely to be
primarily neuroprotective.
Rotenone-induced PD models in SD rats
Chronic systemic exposure to rotenone, a specific com-
plex I inhibitor and common herbicide, has been shown
to reproduce Parkinsonian features in rats. Several research
groups have independently demonstrated that systemically
administered rotenone causes highly selective nigros-
triatal dopaminergic degeneration, which is associated
with the neurochemical, behavioral and neuropatho-
logical features of PD [17-21]. However, considerable
controversy has been reported in terms of the selectivity,
overall degree and reproducibility of the dopaminergic de-
generation [22-28].
Here, we demonstrated that a sublethal dose of
2.0 mg/kg/d s. c. rotenone for 5 weeks induces the full
reproduction of the PD phenotypes, including not only
progressive increases in cataleptic behavior and decreases
in motor coordination and muscle activity, but also
mitochondrial dysfunction and increased ROS and
SNc neurodegeneration of the TH-cells selective to the
striatal region. In our model, bradykinesia and rigidity are
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mitochondrial dysfunction and increased ROS were
evidenced by decreased ATP production and significant
alteration of several major indices of oxidative stress, in-
cluding MDA, SOD, GSH and Trx. It should be stressed
that all of these neurochemical changes are restricted to
the striatal region, which supports the notion that the SNc
is more (and probably most) vulnerable to the impairment
induced by rotenone, likely owing to impaired complex 1
activity and the subsequently elevated ROS. Finally,
severe neuropathological changes were demonstrated in
our model by histology showing massive and selective
loss of TH-positive dopaminergic (DA) neurons in SNc
region. The selective vulnerability of the SNc and DA
neurons to rotenone is not fully understood. It is gener-
ally believed to be largely due to the increased levels of
ROS generated within DA neurons as a result of dopa-
mine metabolism, auto-oxidation and increased iron con-
tent [35]. The recent findings of decreased mitochondrial
mass in the SNc dopamine neurons, as compared to the
mid brain region and frontal cortex in mice [36], may also
contribute to the extraordinary vulnerability of the SNc
DA neurons, though it is not clear whether this is the case
in human brains.
Potent anti-oxidative effect is likely piceid’s key protective
mechanism
Since the original report [37], we have confirmed that
L-dopa administration can prevent rotenone-induced
severe motor deficits to some degree, based on three in-
dependent tests (Figure 2). A comparable and significant
beneficial effect was observed with piceid treatment at
the 40 mg/kg/d dosage. Notably, piceid treatment at a
high oral dosage of 80 mg/kg/d results in a better out-
come in alleviating these motor deficits than L-dopa,
with a 30% and 27% reduction in the grid and bar
tests and > 20% increase in the motor coordination test
(Figure 1, 5 week end-point). This is the first report that
demonstrates the effect of an abundant polyphenol from
natural sources in an animal model of PD.
In Parkinson’s disease, oxidative stress and mitochon-
drial dysfunction underlie the development of neuropath-
ology. In addition to rescuing rats from rotenone-induced
motor behavioral changes, piceid treatment also preserved
mitochondrial ATP levels and counteracted rotenone-
induced elevated ROS selectively in the striatal region. It
is unclear how orally administered piceid can result in a
selective effect in the striatal region that presumably cor-
relates with the most rotenone impaired SNc DA neurons.
We observed a significant reduction in the levels of an
oxidative marker, the lipid peroxidation product MDA,
after piceid treatment. Piceid may detoxify peroxidized
lipid membranes by directly interacting with the pero-
xidated lipids to restore them to lipid alcohols. Piceidtreatment also significantly attenuated rotenone-induced
depletion of GSH in the striatum. A defect in one or more
of the naturally occurring antioxidant defenses, particu-
larly glutathione GSH, is an important factor in the eti-
ology of PD [38]. In fact, depletion in the level of the thiol
reducing agent GSH is the earliest reported biochemical
event to occur in Parkinsonian SNc prior to the selective
loss of complex I activity [39]. Depletion of GSH has been
consistently observed in the nigra of PD patients who have
been diagnosed with incidental Lewy bodies, which has
been established as a preclinical symptom of PD [34]. A
reduction in GSH levels can further impair H2O2 clear-
ance and promote hydroxyl radical formation, leading to
the generation of a pro-oxidant milieu. Similar to GSH,
SOD activity has also been shown to be up-regulated by
piceid treatment. Paradoxically, one earlier study has
reported an elevation in SOD activity following rotenone
exposure [40]. However, in the present study, SOD activity
was found to decrease significantly in the striatum follow-
ing chronic exposure to rotenone. Thus, any of these
defects in enzymatic defense systems could lead to an
imbalance in antioxidant and oxidant species, resulting in
elevated oxidative stress. It would appear that piceid can
enhance the decomposition of H2O2 and dismutation of
superoxide anions by increasing the availability/activity of
GSH and SOD, thereby reducing the damage likely to re-
sult from these devastating free radicals.
The thioredoxin (Trx) system is another antioxidant
system we looked at, in addition to the enzymatic de-
fense systems. Thioredoxin reductase (TrxR), in conjunc-
tion with Trx, is a ubiquitous oxidoreductase system with
antioxidant and redox regulatory roles. Trx, a small
protein with two redox-active disulfide/dithiol sites in its
conserved active site sequence, −Cys-Gly-Pro-Cys-, has a
neuroprotective effect in many experimental systems
[31,41]. There are several reports showing that the benefi-
cial effects of many anti-oxidants depend on their ability
to upregulate and activate the Trx system. Consistently,
thioredoxin reductase deficiency was found to potentiate
ROS and mitochondrial dysfunction and cell death in DA
neurons [42]. However, this has not been seen in PD
patients’ brains, though Trx is reportedly reduced in PD
striatum. Nevertheless, it is tempting to speculate that Trx
plays a crucial role in PD. Co-treatment with a high dose
of piceid (80 mg/kg) resulted in up-regulation of the Trx
protein level in the striatum which completely restored
the reduced Trx protein levels induced by rotenone.
It has long been speculated that piceid can reduce oxi-
dative stress like resveratrol. However, as far as we know,
there was no detailed mechanism to account for how
piceid reduces oxidative stress. Mechanistically, rotenone-
induced dopaminergic neurodegeneration has been gener-
ally attributed to its inhibition of neuronal mitochondrial
complex I [23]. While it is well established that the activity
Chen et al. Molecular Neurodegeneration 2015, 10:4 Page 10 of 14
http://www.molecularneurodegeneration.com/content/10/1/4of the mitochondrial respiratory complex I is reduced in
the SNc of sporadic PD patients [43], several pieces of
recently gathered evidence suggest that rotenone’s effect
may not be solely attributed to impaired complex I activity
[44-47]. In the SY5Y cellular model, we demonstrated that
piceid is a much superior anti-oxidant over resveratrol
against hydrogen peroxide (Liao, unpublished data). How-
ever, we do not know whether these impairments are
secondary, resulting from impaired complex I, nor do we
know which system plays the primary role in mediating
piceid’s anti-oxidative effect. Based on the increasing
knowledge in literatures, it is plausible that Trx system
plays a primary role to attenuate the rotenone-induced
intracellular redox imbalance, oxidative stress, and even-
tual cell death as illustrated in Figure 8. Piceid increases
the levels of Trx protein, altering the transfer of electrons
from NADPH to oxygen and the production of ROS. Fur-
thermore, the lipid peroxidation level is drastically down-
regulated after co-treatment with piceid and both the
availability of GSH and the activity of SOD are signifi-
cantly upregulated. Alternatively, it is also possible that
the increase in the availability of GSH, the activity of SOD
and the up-regulation of Trx protein levels act in combin-
ation to mediate the key mechanisms through which
piceid exerts its antioxidant effect.
Conclusions
In summary, the present study demonstrates that chronic
administration of rotenone to SD rats produces selective
damage to the striatum, possibly by elevating free radical
species and impairs the antioxidant system. Piceid co-Figure 8 Diagram elucidating the proposed model of imbalanced
ROS initiated by disrupted Trx system. Please see text for
detailed discussion.treatment successfully attenuated most of these changes.
We present both in vivo and in vitro evidence to support
that piceid is a strong anti-oxidant in DA neurons. Our
work elucidates the tight correlation between the potent
anti-oxidative activity of piceid and its protective effect on
motor functions. This finding further validates the import-
ant role of mitochondrial dysfunction in the pathogenesis
of PD in this rodent model, as evidenced by a decrease in
striatum ATP levels, which are considered potential bio-
markers for the diagnosis of PD [48]. Our results strongly
support the possible therapeutic potential of piceid as an
antioxidant in PD and other movement disorders where
oxidative stress is a key player in the progression of the
disease. Our findings add to a growing body of evidence
supporting naturally derived anti-oxidants as a new class
of therapeutic options [49].
Methods
Animals, chemicals and drug treatment
Male Sprague Dawley (SD) rats and C57BL/6 mice of
7–8 weeks were obtained from the Laboratory Animal
Center of the Southern Medical University (Certificate
No. 20060015; conferred by the Guangdong Medical
Laboratory Animal Administration Committee) and were
acclimated to the facility for 1 week before the experiments.
Animals were housed 6–8 per cage in a temperature con-
trolled room (21 ± 2°C) with a 12-h on /12-h off light cycle,
and were given ad libitum access to water and food. All
procedures were performed in accordance with the
US NIH’s “Guide for the Care and Use of Laboratory
Animals”, with the approval from the Ethics Committee
at the Southern Medical University, Guangzhou, China.
Piceid was kindly provided by Shenzhen Neptunus
Pharmaceutical Co., Ltd., China (Cat# N03030301). Rote-
none, levodopa (L-dopa), MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine), 6-OHDA (6-hydroxydopamine) were
purchased from Sigma (St. Louis, MO). Assay kits for
determination of malondialdehyde MDA), glutathione
(GSH), superoxide dismutase (SOD), and Adenosine tri-
phosphate (ATP) were supplied by Nanjing Jiancheng
Biotechnology Institute (Nanjing, China). Rotenone was
emulsified in sunflower oil to a concentration of 2.0 mg/
ml as described in several recent studies to be adminis-
tered orally or subcutaneously in rodents [19]. Piceid and
L-dopa were suspended in a 0.5% sodium carboxymethyl-
cellulose (CMC-Na) solution.
Systemic rotenone model of PD and treatments
Male SD rats (weighing 220–240 g) were randomly allo-
cated to six different groups (13–16 animals per group).
The control group received a vehicle of sunflower oil
1.0 ml/kg/d subcutaneously (s. c.) and a vehicle of 0.5%
CMC-Na 10 ml/kg/d orally for 5 weeks. PD neurode-
generation was induced by rotenone s. c. in a dose of
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CMC-Na 10 ml/kg/d orally for 5 weeks. L-dopa and
piceid treatments were performed orally in a dose of
10 mg/kg/d and 20, 40, 80 mg/kg/d in 0.5% CMC-Na
10 ml/kg/d, respectively, for the entire 5 weeks.
Motor behavioral tests
Catalepsy test The development of parkinsonism was
detected by the occurrence of tremors and the observa-
tion of bradykinesia and rigidity in rats were further
quantified by a “Catalepsy test”. The first part was the
grid test where each rat was hung by all four paws on a
vertical grid (25.5 cm wide and 44 cm high with a space
of 1 cm between each wire), and a stopwatch was started
as soon as the rat held onto the grid. The time for the
rats to move its paws or any sort of first movement was
recorded as descent latency.
The second part was the bar test where the rats were
placed with both forepaws on a bar which was 9 cm
above and parallel from the base in a half rearing pos-
ition and they were timed with a stopwatch. When the
animals removed one paw from the bar the stopwatch
was stopped and the latency noted. The maximum des-
cent latency was fixed at 180 s for both tests. Both tests
were repeated once a week to evaluate the disease pro-
gress, starting the first week.
Rotarod motor coordination test The effect of rote-
none on motor coordination and muscle performance
was evaluated using a rotarod (DXP-2) test. The rotarod
treadmill consists of a plastic rod, 9 cm in diameter
and 36 cm long, with a non-slippery surface 20 cm
above the base. This rod is divided into four equal
sections by five discs (25 cm in diameter), which en-
ables four rats to walk on the rod at the same time.
In the present study, all rats were given two initial
training trials of 300 s, approximately 10 min apart,
to maintain posture on the rotarod (rotating at a con-
stant 20 revolutions per minute). After the initial
training trials, a baseline trial of 180 s was conducted.
The time each animal remained on the rotarod was re-
corded by an observer blinded to the treatment groups;
animals not falling off the rotarod were given a maximum
score of 180 s. The test was repeated once a week to eva-
luate motor performance.
Preparation of brain homogenate from rotenone
study At the end of the 5 weeks, all rats were eutha-
nized and brain tissues were collected: striatum, cortex
and hippocampus of the two hemispheres were quickly
excised and weighed. Tissues from half brains were
placed in ice-cold saline (10% w/v) and homogenated
using an electric glass homogenizer, followed by centri-
fugation at 10000 × g for 15 min, 4°C. Since this assay isnot feasible in a denatured environment, no sodium
dodecyl sulfate (SDS) was added to the lysate buffer. The
resulting supernatant was used for the assays of ROS
parameters. Tissues from the other half brains were used
in the preparation of protein lysates for use in Western
blot analysis.
Lipid peroxidation assay Malondialdehyde (MDA), an
end product of the polyunsaturated fatty acid oxygenation
and a reliable and commonly used biomarker for assessing
lipid peroxidation, was determined by thiobarbituric acid
reactive substances (TBARS) according to a published me-
thod [50] (using a commercial kit (Cat#20091014, Nanjing
Jiancheng Biotechnology Institute, China). In brief, 10%
tissue homogenates or MDA standard were mixed with
100 μl of SDS. Then, 2.5 ml of a TBA/Buffer reagent mix
was added and incubated in a boiling water bath for
80 min. The reaction mixture was centrifuged and its
absorbance was measured at 532 nm. The MDA levels are
expressed as MDA nmol/mg of proteins.
Superoxide dismutase (SOD) activity assay The activ-
ity of SOD was determined based on the inhibitory effect
of SOD on nitro blue tetrazolium (NBT) reduction by
the superoxide anions generated by the photo-oxidation
of hydroxylamine hydrochloride. The assessment was
conducted by using the standard kit supplied by Nanjing
Jiancheng Biotechnology Institute (Cat #20091013, China).
Briefly, the assay system consisted of EDTA 0.1 mM, so-
dium carbonate 50 mM and 96 mM of NBT. In the cu-
vette, 2 ml of the above mixture, 0.05 ml of hydroxylamine
and 0.05 ml of 1% brain homogenate were combined
and the auto-oxidation of hydroxylamine was observed
by measuring the absorbance at 550 nm. SOD activity
was expressed as U/mg proteins.
Reduced glutathione assay The amount of reduced
glutathione (GSH) was determined by the amount of
total non-protein sulfhydryl groups. In this method,
GSH reacted with 5, 5′dithio-bis-(2-nitrobenzoic acid)
(DTNB) to develop color absorbance that was measured
at 420 nm. The assessment was conducted by using
standard kits supplied by Nanjing Jiancheng Biotechnology
Institute (Cat #20091125, China), following the manufac-
turer’s instructions. Briefly, 0.5 mL 10% tissue homogenate
was immediately precipitated with 2 ml of 25% TCA and
the precipitate was removed by centrifugation at 1500 × g
for 10 min. 1 ml of the supernatant was added to 1 ml of
DTNB. The absorbance of the yellow color complex was
read at 420 nm. Content of GSH was expressed as mg
GSH/mg proteins.
Adenosine triphosphate content assay Adenosine tri-
phosphate (ATP) levels in the brain tissues were
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Jiancheng Biotechnology Institute, Cat#20091126, China).
The principle is based on the reaction between 3-
phosphoglycerate and ATP catalyzed by phosphoglycerate
kinase. The reaction was coupled with a dephosphorylation
reaction using the enzyme glyceraldehyde phosphate
dehydrogenase (GAPD) that involved the oxidation of
NADH. Formation of NAD was then quantitated by mea-
suring the decrease in absorbance at 340 nm, as a measure
of the amount of ATP. The level of ATP was expressed as
nmol ATP/mg proteins.
Western blot analysis of thioredoxin (Trx) expression
For The hemispheres collected at the end of the 5 week
study (rotenone/piceid) were further dissected to separ-
ate striatum, cortex and hippocampus, samples were
pooled together from 9 rats each group and 75 μg of pro-
tein was loaded for Western blot analysis using a rabbit
polyclonal anti-Trx (1:1,000; Abcam, Hong Kong, Ltd.).
Densitometric analysis was performed using the Quantity
One 4.6.2 software.
Histological analysis of striatal tissues At the end of
the experiment (5 weeks), five rats from each group were
perfused and processed for paraffin embedding. Mid-
brain sections (coronal section of 8 ucrom thickness)
were stained with Hematoxylin and Eosin (H& E) as well
as with an anti-tyrosine hydroxylase/TH antibody (1:100;
Sigma), followed by visualization with 3, 3′-diaminoben-
zidine (Sigma/Aldrich).
6-OHDA induced PD model
Male SD rats (weighing 220–240 g) were randomly
divided into control and model groups (n = 9-10 control
and n > 60 model group). All rats were anesthetized by
intraperitoneal injection of 10% chloral hydrate 3.5 ml/kg,
and were stereotaxically fixed and injected with 6-OHDA
into the right substantia nigra of brains (8 μg in 4 μl at 0.5
ul/min speed) [anterior fontanelle 4.4 mm, sagittal suture
(right) 1.3 mm, 8.5 mm under the skull]. Seven days later,
rats were intraperitoneally injected with 0.5 mg/kg apo-
morphine to induce rat rotating to the contralateral side
and their rotary motion was recorded 30 min later. The
rats that rotated greater than 7 times per minute passed
this test and were continued to be tested on rotarod test
once weekly until 28 days. On day 8 at the time of apo-
morphine injection, the 6-OHDA induced PD rats were
further divided into 4 groups (n = 9–10 each group)
and received daily oral treatment [piceid(50 mg/kg,
l00 mg/kg, L-Dopa (25 mg/kg), L-Dopa (12.5 mg/kg) +
Piceid (50 mg/kg)] starting a few hours after 6-OHDA in-
jection. Their rotary motion was recorded on 7d, 14d, 21d
and 28d.MPTP-induced mouse model of PD and piceid treatment
Male C57BL/6 mice (>25 g) were randomly divided into
three groups, namely the control group, model group
and treatment group (piceid 100 mg/kg, piceid 200 mg/kg,
L-Dopa 50 mg/kg, L-dopa 25 mg/kg + piceid 100 mg/kg).
While the control group received saline by oral gavage,
the model and treatment groups received ip injected
MPTP at 20 mg/kg (0.1 ml/10 g) daily for 7 days. Daily
compound treatments began on day 1 and continued for
14 days. Motor function was assessed on the 15th day by
their locomotor activity counts. In brief, homemade
30 cm× 30 cm× 15 cm plexiglass box which was carved
out of the 6 cm × 6 cm grid at the bottom of box. Mice
were tested in a quiet, low-light environment and were
allowed to be adapted to the environment for 10 min.
Their mobile grid number within 5 min was counted five
times and the mean values were taken. Mice were also
tested on rotarod test to determine motor coordination.
They were placed on a rotating rod instrument (roller
diameter of 6 cm, speed 13 r/min) one hour after of the
last compound/drug administration and were automatic-
ally recorded (maximum detection time 180 s, than those
who still denoted 180 s). Mice were euthanized immedi-
ately after the behavioral tests and the activity of SOD and
the content of MDA of striatum were determined as de-
scribed. For histology, coronal sections (6 μcrom) from
paraffin-embedded mid-brain tissue were stained with H
& E, mouse-anti-TH (Millopore, 1:200), rabbit anti-p-Akt
(Cell Signaling) and rabbit anti-caspase −3 (Cell Signaling),
followed by DAB or fluorescent secondary antibodies.
Statistical analysis All data are presented as mean ±
SEM. The data from the in vivo experiments (Figures 2,
3, 4 and 5) were analyzed using a one-way analysis of
variance (one-way-ANOVA) followed by Newman-Keuls
tests for post hoc comparisons between groups, with the
exceptions of the data of grid test, bar test and rotarod
test, which were analyzed by two-way repeated-measures
ANOVA. All the statistical analyses were conducted
using the Statistical Program of Social Sciences (SPSS) for
windows, version 13.0 and values of p < 0.05 were consid-
ered to be significant.
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6-OHDA-induced PD rats.
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